Search
Registration
Register closed
Registration fee includes:
Access to all scientific and educational sessions of the meeting
Networking opportunities during breaks
Coffee breaks on October 18-20 and lunch on October 19
All fees include VAT.
EHA Mentorship Program overview
Program goalsThe EHA Mentorship Program aims to:
Provide the early and mid-career European hematology community with access to mentorship that's relevant to their career stage
Expose hematologists and researchers from less professionally mobile backgrounds to career mentorship and best practices from other…
Trial membership
Are you interested in connecting with EHA and our vibrant community, but you're not yet ready to apply for membership?
By becoming an EHA guest, you can enjoy 60 days of free access to:
The European Hematology Curriculum
Select courses on EHA Campus
You'll…
Joint EHA and national society membership
Enjoy the best of both worlds—and save money—by combining an EHA membership with membership of your national hematology society. This special type of membership package is the result of our constructive collaborations with a range of national hematology societies.
Read moreSponsor opportunities
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…
Read moreHelp disseminate IVDR Questionnaire - Share with diagnostic laboratories in your network
The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.
Read moreEHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021
Chairs: H Einsele (EHA) & C Chabannon (EBMT)
For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…
Does the patient with myelofibrosis feel better through Pacritinib?
Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.
Read moreIs CRTH for me?
Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD
Applicant must be actively employed in a hematology or hematology-related research environment
The applicant must be an EHA member or EHA Guest at the time of application submission…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- »